BOD Australia Ltd Company Profile
ASX:BDA

A global downstream medicinal cannabis opportunity

Bod Australia is a developer, distributor and marketer of health and skincare products with expertise in leveraging the health benefits associated with cannabis and hemp.

  • Company
    BOD Australia Ltd
  • Website
  • Sector
    Distributors
  • Industry
    Distributors
  • Code
    ASX:BDA
  • Socials

Company Overview

Star icon Promoted

Bod Australia Limited (ASX:BDA, Bod) is a developer and distributor of natural, evidence-based health products with a focus on plant-based extracts and medicinal cannabis. Bod is actively commercialising a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical-grade cannabis extracts.

The company has an extensive distribution footprint in Australia, selling a variety of prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. Bod has also partnered with the innovation arm of the multi-billion-dollar Hong Kong listed H&H group, NewH2, to commercialise a range of OTC products using Bod's extracts. NewH2 is a recent strategic investor in Bod after investing $5.5m for a 17.64% stake in the company.

Share this profile:

Global growth potential in the downstream medicinal cannabis market.

Bod Australia is primed to accelerate sales within the $13.4bn medicinal cannbis markets via its multiple strategic partnerships.
Triple-Digit Growth

Recently achieved over 860% growth in medicinal cannabis prescription volumes quarter-on-quarter, making Bod one of nation's top medicinal cannabis providers.

Global Partner

Multi-billion-dollar health and wellness behemoth Health & Happiness (H&H) are a new strategic investor and partner to commercialise a range of Bod's CBD products.

Research

Bod continues to collaborate with other thought leaders and is one of the five companies invited to participate in Europe’s largest medicinal cannabis project targeting 20,000 patients.

Introducing Medicablis

Through its partnership with Swiss Botanicals extracts manufacturer Linnea SA, Bod supplies its pharmaceutical-grade cannabis extract, MediCabilis™ 5% CBD ECs315 (MediCabilis™) via prescription. Phase 1 trials have demonstrated that Bod's oil extract and sublingual wafer have been deemed safe for human consumption showing excellent tolerability characteristics. MediCabilis™ is currently available via the Special Access Scheme (SAS-B) in the domestic market.

Latest presentation

Click here to download Bod Australia's latest presentation

Growing Sales

Prescriptions of Bod's MediCabilis™ have continued to increase as it has continued to gain wider acceptance within the medical community. Strong uptake continues through its distribution partner Burleigh Heads Cannabis and its partner Company, Cannabis Doctors Australia. A 12-month trial under-taken by Cannabis Access Clinics, relating to Post Traumatic Stress Disorder (PTSD) is also underpinning sales for Bod.

Prescription Growth

Click here to learn more about Bod's Prescription Growth

Distribution Partners & Expansion

Bod will expand MediCabilis™ sales into the U.K. through a medicinal cannabis distribution agreement with PCCA Ltd. PCCA are an MHRA licensed medicines manufacturer with a 4,000 strong network of hospitals, physicians, clinics and medical specialists.

Learn more about PCCA

Click here to learn more about Bod Australia's exciting PCCA partnership.

Major Global Strategic Investor & Partner

NewH2, the innovation arm of multi-billion dollar Health & Happiness Group Ltd (H&H Group/HKSE:112), invested $5.5m to acquire 17.64% of Bod. H&H Group is a global leader in premium-quality adult and baby nutrition and care products listed on the Hong Kong Stock Exchange. The Group will leverage its global footprint to market and distribute H&H labelled products supplied by Bod with a near term focus on the UK, USA, France, Italy and the Netherlands.

Fully funded for aggressive growth

In addition to its $5.5m investment in Bod, $1.5m was also paid by H&H Group for the exclusive global licence to commercialise Bod’s CBD and hemp products. This arrangement has strengthened Bod's balance sheet while also allowing it to pursue an aggressive global growth agenda without significant capital outlay. Furthermore, over $1.2m was raised from the exercise of board and management options, which further strengthened Bod's balance sheet.

Read the H&H Announcement

Click here to view the H&H partnership announcement

Research Ongoing

Bod continues to collaborate with thought leaders in the Cannabis space. Bod Australia is 1 of 5 companies globally invited to participate in Project Twenty21, Europe’s largest medicinal cannabis project and will study the effects of cannabis when used on patients with chronic conditions. Other research includes a landmark 12-month trial facilitated by Cannabis Access Clinics for Post Traumatic Stress Disorder (PTSD) and a collaboration with UTS to uncover a novel delivery system that can combat the skin aging process.

Project Twenty21

Click here to learn more about Project Twenty21 and Bod Australia's involvement.

Strong board and management

Bod's leadership team have extensive experience working at top tier international brands. Bod also recently further strengthened its team with the appointment of Mr. Mark Masterson as its non-executive chairman. Mr Masterson held several global leadership positions across the USA, Europe, Asia and Australia during his time at global pharmaceutical behemoth Abbott Laboratories. In addition, he was the Chief Executive Officer of Australia's largest private diagnostic imaging network, I-MED, and was previously appointed as Chairman of Medicines Australia.
Clock icon Information current at 08 November 2019

Company Videos

2 Videos

News Coverage

Current news mentioning BOD Australia Ltd from top publishers around the web.
Powered by  

Key Announcements

Management comments and explanations on key company announcements.
Need a full list of every announcement? Visit ASX

How do I invest?

Considering investing in BOD Australia Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:BDA

    On your online investment platform search for the stock ticker code ASX:BDA to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up